Loading
companiesCompany
Dr. Reddy's Laboratories
The Hyderabad generics maker that launched the world's first rituximab biosimilar in 2007 and now sells oncology generics and biosimilars in India, the US and Europe.
Overview
Dr. Reddy's was founded in 1984 by Kallam Anji Reddy and is listed on the NSE, BSE and NYSE. It was an early mover in biosimilars: its rituximab, Reditux, was approved in India in 2007, the first rituximab biosimilar anywhere, and its EU rituximab (Ituxredi) was authorised in September 2024 at a price several times below the reference brand. The company is a major supplier of oncology generics (abiraterone, bortezomib, azacitidine, decitabine and many injectables) to the US and India, and its oncology-focused subsidiary Aurigene runs discovery and clinical programmes. Dr. Reddy's also in-licenses innovative oncology products for India.
Headquarters
Hyderabad, IN
Scorecard
All companies#51of 1244 companies, score 71
- approved products +24
- targets +4
- modalities +4
- regions +7
- 24-month regulatory events +2
- registry trials +30
4 approved, 0 in phase 3, 0 earlier, 2 targets, 3,880 registry studies. Formula on the scorecards page.
Type
Large pharma · RDY
Stage
Public
Website
Founded
1984
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
ApprovedSmall-molecule CYP17A1 inhibitor
Abiraterone acetate · Zytiga (generic)
Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis.
ApprovedProteasome inhibitor
Bortezomib · Velcade
Bortezomib was the first proteasome inhibitor: it jams the cell's protein-recycling machine, which antibody-factory plasma cells cannot tolerate.
ApprovedSmall-molecule hypomethylating agent (cytotoxic)
Azacitidine · Vidaza / Onureg (oral)
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
Similar pages
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Biosimilar, Generic sterile injectables (the 2023 platinum shortage).
- CompanyHetero Drugs
Shares Biosimilar, CD20, Prices and value, Rituximab.
- CompanyCipla
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
- CompanyViatris
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Biosimilar, Generic sterile injectables (the 2023 platinum shortage).
- CompanyBiocon
Shares Biosimilar manufacturing and comparability, Biosimilar, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
- CompanySun Pharmaceutical Industries
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis, Abiraterone acetate, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
- CompanySandoz
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Generic sterile injectables (the 2023 platinum shortage).
- CompanyBiocon Biologics
Shares Biosimilar, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
fronts
technologies
targets
drugs
ApprovedSmall-molecule CYP17A1 inhibitor
Abiraterone acetate · Zytiga (generic)
ApprovedSmall-molecule hypomethylating agent (cytotoxic)
Azacitidine · Vidaza / Onureg (oral)
ApprovedProteasome inhibitor
Bortezomib · Velcade
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)